Various aspects of this disclosure relate generally to agent delivery systems, devices, and related methods. More specifically, at least certain embodiments of the disclosure relate to systems, devices, and related methods for metering a dose of a therapeutic agent delivered to a target treatment site, among other aspects.
In certain medical procedures, it may be necessary to stop or minimize bleeding internal to the body. For example, an endoscopic medical procedure may require hemostasis of bleeding tissue within the gastrointestinal tract, for example in the esophagus, stomach, or intestines.
During an endoscopic procedure, a user inserts a sheath of an endoscope into a body lumen of a patient. The user utilizes a handle of the endoscope to control the endoscope during the procedure. Tools are passed through a working channel of the endoscope via, for example, a port in the handle, to deliver treatment at the procedure site near a distal end of the endoscope. The procedure site is remote from the operator.
To achieve hemostasis at the remote site, a hemostatic agent may be delivered. Agent delivery may be achieved by utilizing pressurized fluid systems, for example. Such systems, however, may provide difficulties in controlling a delivery rate of the agent. Accordingly, a desired rate of agent delivery or a desired dosage of agent may not be achieved, which may result in the agent clogging portions of the delivery device, may result in inconsistent dosing of agent, or may not result in the agent reaching the treatment site deep within the GI tract. This disclosure may solve one or more of these issues or other issues in the art.
Aspects of the disclosure relate to, among other things, systems, devices, and methods for metering delivery of a dose of an agent, among other aspects. Each of the aspects disclosed herein may include one or more of the features described in connection with any of the other disclosed aspects.
According to an example, a medical device includes an enclosure for storing an agent, an agitator positioned adjacent to or within the enclosure and configured to oscillate relative to the enclosure, and an outlet having a first end in fluid communication with the enclosure and a second end in fluid communication with a channel of a delivery tube. Oscillation of the agitator causes the agent to move toward the outlet.
Any of the medical devices described herein may have any of the following features. The delivery tube is in fluid communication with a pressurized medium source that stores a pressurized fluid. The delivery tube receives the pressurized fluid through the delivery tube such that the delivery tube is configured to deliver the agent received from the outlet through the delivery tube via the pressurized fluid. The enclosure is fluidly coupled to a pneumatic system via a valve, wherein the pneumatic system stores a second pressurized fluid. The valve is configured to permit delivery of the second pressurized fluid from the pneumatic system to the enclosure in response to actuation of the valve. The agitator is configured to oscillate relative to the enclosure in response to the enclosure receiving the second pressurized fluid from the pneumatic system. The agent includes a hemostatic powder. The agitator includes a diaphragm, a plunger, a piston, or an auger conveyor. The outlet includes a valve. The agitator includes a diaphragm and one or more walls that define a void, wherein at least one of the one or more walls is configured to move relative to the enclosure in response to movement of the diaphragm. The diaphragm and the at least one of the one or more walls are configured to oscillate when a pressurized medium is received within the void. Further including a coupling rod and a wheel, wherein the coupling rod has a first end coupled to the wheel and a second end coupled to the agitator. The coupling rod is configured to oscillate the agitator in response to the wheel rotating. The wheel is coupled to a motor that is operable to rotate the wheel.
According to another example, a medical device includes an enclosure for storing an agent. The medical device includes an agitator positioned adjacent to or within the enclosure. The agitator is configured to create pressure change within the enclosure via oscillation of the agitator relative to the enclosure. The medical device includes an outlet having a first end in fluid communication with the enclosure and a second end in fluid communication with a delivery tube. In response to oscillation of the agitator the agent is positioned towards the delivery tube, such that initiating a pressurized fluid propels the agent through the delivery tube.
Any of the medical devices described herein may have any of the following features. The outlet is configured to control a dose of the agent outputted from the enclosure toward the delivery tube. The agitator includes a diaphragm, one or more walls coupled to the diaphragm, and a void defined between the diaphragm and the one or more walls. The diaphragm is configured to oscillate relative to the enclosure in response to the void receiving a pressurized medium and at least one of the one or more walls moving away from the diaphragm. The agitator includes a piston that is configured to oscillate relative to the enclosure in response to the piston receiving a force that is generated by a motor.
According to another example, a method of delivering an agent to a target site via a medical device that includes an enclosure, an agitator, and a delivery tube, includes oscillating the agitator relative to the enclosure to direct the agent stored within the enclosure to the delivery tube. The agitator is oscillated in response to actuation of a first source of pressure that is in fluid communication with the enclosure. The method includes delivering the agent to the target site via the delivery tube, in response to actuation of a second source of pressure that is in fluid communication with the delivery tube.
It may be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate exemplary aspects of the present disclosure and together with the description, serve to explain the principles of the disclosure.
This disclosure is drawn to systems, devices, and methods for endoscopic delivery of, for example, a hemostatic agent, among other aspects. Reference will now be made in detail to aspects of the disclosure, examples of which are illustrated in the accompanying drawings. Wherever possible, the same or similar reference numbers will be used through the drawings to refer to the same or like parts. The term “distal” refers to a portion farthest away from a user when introducing a device into a patient. By contrast, the term “proximal” refers to a portion closest to the user when placing the device into the patient. As used herein, the terms “comprises,” “comprising,” or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not necessarily include only those elements, but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. The term “exemplary” is used in the sense of “example,” rather than “ideal.” As used herein, the terms “about,” “substantially,” and “approximately,” indicate a range of values within +/−10% of a stated value.
Embodiments of this disclosure may be used to deliver a material to a target treatment site experiencing bleeding to achieve hemostasis. For example, a hemostatic agent in the form of a powder may be delivered to treat a gastrointestinal bleed by a medical device that includes an agitator that oscillates to deliver the hemostatic agent. In some embodiments, the agitator may oscillate to deliver the hemostatic agent via systems that are separate from a delivery mechanism of the medical device. Embodiments of the disclosure are not limited to such devices and methods, and instead may relate to devices and methods for performing various medical procedures and/or treating portions of the large intestine (colon), small intestine, cecum, esophagus, any other portion of the gastrointestinal tract, and/or any other suitable patient anatomy (collectively referred to herein as a “target treatment site”). Various embodiments described herein include single-use or disposable medical devices.
In one exemplary embodiment a medical device for delivering the hemostatic material may include an enclosure for storing an agent and an agitator positioned adjacent to or within the enclosure, with the agitator of the medical device capable of oscillating relative to the enclosure. The medical device further includes an outlet having a first end in fluid communication with the enclosure and a second end in fluid communication with a channel of a delivery tube. The oscillation of the agitator is configured to provide movement of the agent toward the first end of the outlet and to the second end of the outlet such that the agent is received within the delivery tube. Reference will now be made in detail to examples of the disclosure described above and illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.
The proximal portion 110 of the medical system 100 may further include a housing 111 that is sized and shaped to store one or more components of the proximal portion 110 therein. In the embodiment, the housing 111 is positioned adjacent to the distal end 12 of the body 10, however, it should be understood that the housing 111 may be located at various other positions along the body 10. Additionally and/or alternatively, in other embodiments the housing 111, for example, the one or more components stored within the housing 111, may be disposed within the body 10.
Referring now to
In the embodiment, the first pressurized medium source 102 is in fluid communication with the housing 111 of the proximal portion 110 via an inlet 104, such that a first end of the inlet 104 is fluidly coupled to the first pressurized medium source 102 and a second end of the inlet 104 is fluidly coupled to the housing 111. The proximal portion 110 may include a valve 106 positioned within the inlet 104 and configured to control a rate of delivery of pressurized medium from the first pressurized medium source 102 to the housing 111. In some embodiments, the valve 106 may include, for example, a relief valve, a duckbill valve, a shelf, a rotatable wheel, and/or various other suitable devices capable of controlling and/or limiting a rate of delivery of the pressurized medium from the first pressurized medium source 102 to the housing 111 via the inlet 104. For instance, the valve 106 may be electrically actuatable by a user of the proximal portion 110 to control delivery of the pressurized medium. In other embodiments, the first pressurized medium source 102 may include a pressure regulator mechanism in addition to and/or in lieu of the valve 106 for controlling and/or limiting delivery of the pressurized medium to the housing 111. By way of further example, in some embodiments the valve 106 may include an orifice having a predefined and/or adjustable size (e.g., diameter) to regulate a delivery rate of the pressurized medium.
In the embodiment, the housing 111 is in fluid communication with the delivery tube 114 via an outlet 116, such that a first end of the outlet 116 is fluidly coupled to the housing 111 and a second end of the outlet 116 is fluidly coupled to the delivery tube 114. A valve 118 is positioned within the outlet 116 and configured to control a rate of delivery of a material stored in the housing 111 (e.g., an agent 50) to the delivery tube 114. In some embodiments, the valve 118 may include for example, a relief valve, a duckbill valve, a shelf, a rotatable wheel, and/or various other suitable devices capable of controlling and/or limiting a rate of delivery of the agent 50 from the housing 111 to the delivery tube 114 via the outlet 116.
Still referring to
In the embodiment, the agitator 120 may include a diaphragm 122, a central rod 124, a fixed floor 125, a movable ceiling 126, and a pair of sidewalls 128. The diaphragm 122 of the agitator 120 may be formed of a flexibly deformable material such that the diaphragm 122 is configured to flex in response to movement of the diaphragm 122 relative to the enclosure 112. For example, the diaphragm 122 may be at least partially formed as a silicon (Si) membrane, a low-density polyethylene (LDPE) polymer, and/or the like. As described in greater detail herein, the diaphragm 122 is configured to move relative to the enclosure 112 in response to the housing 111 receiving a pressurized medium from the first pressurized medium source 102.
The diaphragm 122 is secured to, and extends between, the pair of sidewalls 128 of the agitator 120 such that the opposing terminal ends of the diaphragm 122 are coupled to the pair of sidewalls 128. Further, the diaphragm 122 is coupled to the central rod 124 along an intermediate portion of the diaphragm 122. In the embodiment, the diaphragm 122 is coupled to a first end of the central rod 124 and the movable ceiling 126 is coupled to a second end of the central rod 124. Accordingly, the diaphragm 122 is separated from the movable ceiling 126 by a longitudinal length of the central rod 124 disposed therebetween. The agitator 120 defines a void 130 between the diaphragm 122 and the movable ceiling 126 and, as described further herein, the agitator 120 is configured to receive a pressurized medium from the first pressurized medium source 102 in the void 130.
Still referring to
With the movable ceiling 126 coupled to the central rod 124, and the central rod 124 further coupled to the diaphragm 122, the movable ceiling 126 is operable to move the central rod 124 and the diaphragm 122 in response to movement (e.g., translation) of the movable ceiling 126 relative to the pair of sidewalls 128. It should be appreciated that a size, shape, profile and/or configuration of the enclosure 112 and/or the agitator 120 shown and described herein is merely illustrative such that the enclosure 112 and/or the agitator 120 may include various other suitable arrangements without departing from a scope of this disclosure.
Still referring to
As described in further detail herein, the fixed floor 125 is configured to engage the diaphragm 122 of the agitator 120 as the central rod 124 and the movable ceiling 126 move relative to the pair of sidewalls 128 (e.g., in an upward direction). In this instance, the fixed floor 125 is operable to form an impediment for a further translation of the central rod 124 and/or deformation of the diaphragm 122 beyond a predetermined extent relative to the enclosure 112 and/or the pair of sidewalls 128. It should be understood that, in other embodiments, the fixed floor 125 of the agitator 120 may be omitted entirely such that the central rod 124 and/or the diaphragm 122 may translate and deform to various other suitable extents than those shown and described herein, respectively.
According to an example method of using the medical system 100, the agent 50 may be initially stored in the enclosure 112 of the housing 111 and the insertion portion 109 may be fluidly coupled to the delivery tube 114 of the proximal portion 110 (e.g., at the port 16 of the body 10). In this instance, upon activation of the first pressurized medium source 102, a pressurized medium may be transmitted to the housing 111 via the inlet 104. The pressurized medium may be delivered in a direction B through the inlet 104 and into the housing 111 via the valve 106. The agitator 120 may receive the pressurized medium within the void 130, thereby causing the movable ceiling 126 to move relative to the pair of sidewalls 128 in response. For example, the movable ceiling 126 may move away from the diaphragm 122 as the void 130 receives the pressurized medium therein such that the central rod 124 moves (e.g., translates) simultaneously with the movable ceiling 126. With the central rod 124 coupled to the diaphragm 122, the diaphragm 122 is configured to move relative to the enclosure 112 and toward the movable ceiling 126.
Referring now to
In the embodiment, movement of the diaphragm 122 of the agitator 120 creates a pressure change within the enclosure 112 of the housing 111, thereby causing the agent 50 stored within the enclosure 112 to move. The diaphragm 122 is configured to oscillate relative to the enclosure 112 in response to the first pressurized medium source 102 delivering the pressurize medium to the housing 111 via the inlet 104 and the valve 106 controlling and/or limiting a rate of delivery of the pressurized medium. Accordingly, the diaphragm 122 of the agitator 120 may repeatedly oscillate relative to the enclosure 112 to a plurality of positions relative to an initial position (see
Still referring to
Additionally and/or alternatively, a dose of the agent 50 received by the insertion portion 109 may be metered by controlling an activation of the first pressurized medium source 102. As noted above, in some embodiments the first pressurized medium source 102 may include a pressure regulator mechanism for controlling and/or limiting delivery of the pressurized medium to the housing 111. The pressure regulator mechanism of the first pressurized medium source 102 may, for example, automatically activate and deactivate the first pressurized medium source 102 to selectively deliver the first pressurized medium to the housing 111 to cause an oscillation of the agitator 120. In this instance, initiating and stopping the first pressurized medium source 102 may provide a controlled delivery of the pressurized medium source thereby resulting in an alternating increase and decrease of pressure within the housing 111 and the enclosure 112 where the agitator 120 is positioned.
Referring now to
In the embodiment, the movable ceiling 126 of the agitator 120 is coupled to the wheel 206 via a coupling rod 208 such that rotation of the wheel 206 may provide movement of the movable ceiling 126 relative to the enclosure 112 and/or the pair of sidewalls 128. For example, the proximal portion 210 may be configured such that rotation of the wheel 206 provides a translation of the movable ceiling 126 of the agitator 120. With the movable ceiling 126 coupled to the central rod 124, and the central rod 124 further coupled to the diaphragm 122, movement (e.g., translation) of the movable ceiling 126 may cause simultaneous movement (e.g., translation) of the central rod 124 and/or deformation of the diaphragm 122 relative to the enclosure 112. It should be understood that, in some embodiments, the motor 202, the rod 204, and/or the wheel 206 is disposed within the body 10 of the proximal portion 210 and, in other embodiments, may be positioned external to the body 10 of the proximal portion 210.
According to an example method of using the medical system 200, the agent 50 may be initially stored in the enclosure 112 of the housing 111 and the insertion portion 109 may be fluidly coupled to the delivery tube 114 of the proximal portion 210 (e.g., at the port 16 of the body 10). In this instance, upon activation of the motor 202, the wheel 206 may be rotated, such as, for example, in a clockwise and/or counterclockwise direction relative to the housing 111 and/or the enclosure 112. Rotation of the wheel 206 may transmit an oscillating force onto the agitator 120 (e.g., a pulling-force, a pushing-force, etc.), for example, onto the movable ceiling 126, such that the movable ceiling 126 moves relative to the pair of sidewalls 128 in response. For example, the movable ceiling 126 may move away from the diaphragm 122 as the wheel 206 rotates such that the central rod 124 moves (e.g., translates) simultaneously with the movable ceiling 126. With the central rod 124 coupled to the diaphragm 122, the diaphragm 122 is configured to move relative to the enclosure 112 and toward the movable ceiling 126.
Referring now to
In the embodiment, movement of the diaphragm 122 of the agitator 120 creates a pressure change within the enclosure 112 that causes the agent 50 stored within the enclosure 112 to move. The diaphragm 122 is configured to oscillate relative to the enclosure 112 in response to the motor 202 causing rotation of the wheel 206. Accordingly, the diaphragm 122 of the agitator 120 may repeatedly oscillate relative to the enclosure 112 to a plurality of positions relative to an initial position (see
Still referring to
Referring now to
In the embodiment, the agitator 320 may include a piston, a plunger, an auger conveyor, and/or any other like structure. For example, the agitator 320 may include a crown 322 and a rod shaft 324. The motor 202 is coupled to the agitator 320 via the inlet 104, for example, the motor 202 is coupled to the rod shaft 324 which extends through the inlet 104. The crown 322 of the agitator 320 is positioned at a distal end of the rod shaft 324 opposite of a proximal end of the rod shaft 324 that is coupled to the motor 202. Accordingly, actuation of the motor 202 is communicated to the crown 322 of the agitator 320 via the rod shaft 324. The rod shaft 324 is configured to move in response to actuation of the motor 202 and, as described in greater detail herein, cause oscillation of the crown 322 of the agitator 320 in response. For example, the proximal portion 310 may be configured such that translation of the rod shaft 324 relative to the inlet 104 provides a translation of the crown 322 of relative to the enclosure 112 and/or the housing 111. It should be understood that, in some embodiments, the motor 202 is disposed within the body 10 of the proximal portion 310 and, in other embodiments, may be positioned external to the body 10 of the proximal portion 310.
According to an example method of using the medical system 300, the agent 50 may be initially stored in the enclosure 112 of the housing 111 and the insertion portion 109 may be fluidly coupled to the delivery tube 114 of the proximal portion 310 (e.g., at the port 16 of the body 10). In this instance, upon activation of the motor 202, the rod shaft 324 of the agitator 320 may be moved relative to the housing 111 and/or the enclosure 112. Translation of the rod shaft 324 may transmit a force onto the crown 322 of the agitator 320 (e.g., a pulling-force, a pushing-force, etc.), such that the crown 322 moves relative to the enclosure 112 in response. It should be appreciated that, in other embodiments, the medical system 300 may include the first pressurized medium source 102 in lieu of the motor 202 for actuating the agitator 320 of the proximal portion 310.
Referring now to
Still referring to
Each of the aforementioned devices, assemblies, and methods may be used to provide controlled delivery of, for example, a hemostatic agent to a target treatment site. Any of the medical systems 100, 200, 300, for example, the insertion portions 109 of the medical systems 100, 200, 300 shown and described above, may be inserted into an endoscope, or like device, with imaging systems, lighting systems, etc., to assist in positioning the medical systems 100, 200, 300. By providing a surgical assembly that allows a user to interact with a patient's tissue experiencing a bleed using an agitator during a procedure, a user may reduce overall procedure time, increase efficiency of procedures, and avoid unnecessary harm to a patient's body caused by limited access to target tissue of a patient and/or ineffectiveness in coagulating the bleed.
It will be apparent to those skilled in the art that various modifications and variations may be made in the disclosed devices and methods without departing from the scope of the disclosure. Other aspects of the disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the features disclosed herein. It is intended that the specification and examples be considered as exemplary only.
This application claims the benefit of priority from U.S. Provisional Application No. 62/957,540, filed on Jan. 6, 2020, which is incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
471854 | Howard | Mar 1892 | A |
881238 | Hasbrouck | Mar 1908 | A |
1145520 | Smith | Jul 1915 | A |
1599959 | Buheiji | Sep 1926 | A |
1732566 | McKendrick | Oct 1929 | A |
2151418 | Bolté | Mar 1939 | A |
2185927 | Shelanski | Jun 1940 | A |
2478715 | Schmitt | Aug 1949 | A |
2623519 | Cohen | Dec 1952 | A |
3653380 | Hansen | Apr 1972 | A |
3669113 | Altounyan et al. | Jun 1972 | A |
3940061 | Gimple et al. | Feb 1976 | A |
4184258 | Barrington et al. | Jun 1980 | A |
4427450 | Kostansek | Jan 1984 | A |
4457329 | Werley et al. | Jul 1984 | A |
4806167 | Raythatha | Feb 1989 | A |
4836417 | Uchiyama | Jun 1989 | A |
5215221 | Dirksing | Jun 1993 | A |
5231983 | Matson et al. | Aug 1993 | A |
5273531 | Knoepfler | Dec 1993 | A |
5312331 | Kneopfler | May 1994 | A |
5312333 | Churinetz et al. | May 1994 | A |
5366122 | Guentert et al. | Nov 1994 | A |
5445612 | Terakura | Aug 1995 | A |
5470311 | Setterstrom et al. | Nov 1995 | A |
5884621 | Matsugi et al. | Mar 1999 | A |
5951531 | Ferdman et al. | Sep 1999 | A |
6003512 | Gerde | Dec 1999 | A |
6484750 | Foos et al. | Nov 2002 | B1 |
6554022 | Wakeman | Apr 2003 | B2 |
6589087 | Mackal et al. | Jul 2003 | B2 |
6684917 | Zhu et al. | Feb 2004 | B2 |
6708712 | Wakeman | Mar 2004 | B2 |
6716190 | Glines et al. | Apr 2004 | B1 |
6799571 | Hughes et al. | Oct 2004 | B1 |
7178547 | Mackal | Feb 2007 | B2 |
7311270 | Kapila | Dec 2007 | B2 |
7334598 | Hollars | Feb 2008 | B1 |
7361300 | Kelly et al. | Apr 2008 | B2 |
7427607 | Suzuki | Sep 2008 | B2 |
7455248 | Kablik et al. | Nov 2008 | B2 |
7461649 | Gamard et al. | Dec 2008 | B2 |
7544177 | Gertner | Jun 2009 | B2 |
7563299 | Baptista da Costa et al. | Jul 2009 | B2 |
7673647 | Mackal | Mar 2010 | B2 |
7841338 | Dunne et al. | Nov 2010 | B2 |
7892205 | Palasis et al. | Feb 2011 | B2 |
7921874 | Tekulve et al. | Apr 2011 | B2 |
8037880 | Zhu et al. | Oct 2011 | B2 |
8097071 | Burgess et al. | Jan 2012 | B2 |
8118777 | Ducharme et al. | Feb 2012 | B2 |
8269058 | McCarthy et al. | Sep 2012 | B2 |
8313474 | Campbell et al. | Nov 2012 | B2 |
8360276 | Rogier et al. | Jan 2013 | B2 |
8361054 | Ducharme et al. | Jan 2013 | B2 |
8496189 | Lomond et al. | Jul 2013 | B2 |
8673065 | Burgess et al. | Mar 2014 | B2 |
8721582 | Ji | May 2014 | B2 |
8728032 | Ducharme et al. | May 2014 | B2 |
8741335 | McCarthy | Jun 2014 | B2 |
8827980 | Ji | Sep 2014 | B2 |
8910627 | Iwatschenko et al. | Dec 2014 | B2 |
8951565 | McCarthy | Feb 2015 | B2 |
9028437 | Ott et al. | May 2015 | B2 |
9089658 | Dunne et al. | Jul 2015 | B2 |
9101744 | Ducharme | Aug 2015 | B2 |
9107668 | Melsheimer et al. | Aug 2015 | B2 |
9132206 | McCarthy | Sep 2015 | B2 |
9204957 | Gregory et al. | Dec 2015 | B2 |
9205170 | Lucchesi et al. | Dec 2015 | B2 |
9205207 | Ji | Dec 2015 | B2 |
9205240 | Greenhalgh et al. | Dec 2015 | B2 |
9308584 | Burgess et al. | Apr 2016 | B2 |
9310812 | Costle et al. | Apr 2016 | B2 |
9375533 | Ducharme et al. | Jun 2016 | B2 |
9492646 | Hoogenakker et al. | Nov 2016 | B2 |
9517976 | Mackal | Dec 2016 | B2 |
9545490 | Iwatschenko et al. | Jan 2017 | B2 |
9555185 | Foster et al. | Jan 2017 | B2 |
9629966 | Ji | Apr 2017 | B2 |
9636470 | Pohlmann et al. | May 2017 | B2 |
9707359 | Kubo | Jul 2017 | B2 |
9713682 | Eistetter et al. | Jul 2017 | B2 |
9717897 | Rogier | Aug 2017 | B2 |
9821084 | Diegelmann et al. | Nov 2017 | B2 |
9839772 | Ducharme | Dec 2017 | B2 |
9839774 | Bonaldo | Dec 2017 | B2 |
9846439 | Carman et al. | Dec 2017 | B2 |
9867931 | Gittard | Jan 2018 | B2 |
9976660 | Stanton et al. | May 2018 | B2 |
10004690 | Lee et al. | Jun 2018 | B2 |
10010705 | Greenhalgh et al. | Jul 2018 | B2 |
10017231 | Fawcett, Jr. | Jul 2018 | B2 |
10036617 | Mackal | Jul 2018 | B2 |
10065004 | Eder | Sep 2018 | B2 |
10173019 | Kaufmann et al. | Jan 2019 | B2 |
10384049 | Stanton et al. | Aug 2019 | B2 |
10463811 | Lee et al. | Nov 2019 | B2 |
10507293 | Goodman et al. | Dec 2019 | B2 |
10646706 | Rogier | May 2020 | B2 |
10730595 | Fawcett | Aug 2020 | B2 |
10751523 | Rogier | Aug 2020 | B2 |
10806853 | Gittard | Oct 2020 | B2 |
10850814 | Fawcett | Dec 2020 | B2 |
10994818 | Hernandez | May 2021 | B2 |
20040107963 | Finlay et al. | Jun 2004 | A1 |
20040249359 | Palasis et al. | Dec 2004 | A1 |
20050121025 | Gamard et al. | Jun 2005 | A1 |
20050147656 | McCarthy et al. | Jul 2005 | A1 |
20050220721 | Kablik et al. | Oct 2005 | A1 |
20060004314 | McCarthy et al. | Jan 2006 | A1 |
20060038027 | O'Connor | Feb 2006 | A1 |
20060213514 | Price et al. | Sep 2006 | A1 |
20070056586 | Price et al. | Mar 2007 | A1 |
20070066920 | Hopman et al. | Mar 2007 | A1 |
20070066924 | Hopman et al. | Mar 2007 | A1 |
20070082023 | Hopman et al. | Apr 2007 | A1 |
20070125375 | Finlay et al. | Jun 2007 | A1 |
20070151560 | Price et al. | Jul 2007 | A1 |
20070083137 | Hopman et al. | Aug 2007 | A1 |
20070199824 | Hoerr et al. | Aug 2007 | A1 |
20080021374 | Kawata | Jan 2008 | A1 |
20080192565 | Johnson | Aug 2008 | A1 |
20080287907 | Gregory et al. | Nov 2008 | A1 |
20090101144 | Gamard et al. | Apr 2009 | A1 |
20090155342 | Diegemann et al. | Jun 2009 | A1 |
20090281486 | Ducharme | Nov 2009 | A1 |
20100121261 | Kablik et al. | May 2010 | A1 |
20100305505 | Ducharme et al. | Dec 2010 | A1 |
20110073200 | Overvaag et al. | Mar 2011 | A1 |
20110274726 | Guo et al. | Nov 2011 | A1 |
20110308516 | Price et al. | Dec 2011 | A1 |
20130218072 | Kubo | Aug 2013 | A1 |
20140271491 | Gittard et al. | Sep 2014 | A1 |
20150094649 | Gittard | Apr 2015 | A1 |
20150125513 | McCarthy | May 2015 | A1 |
20160375202 | Goodman et al. | Dec 2016 | A1 |
20170106181 | Bonaldo et al. | Apr 2017 | A1 |
20170232141 | Surti et al. | Aug 2017 | A1 |
20170252479 | Ji et al. | Sep 2017 | A1 |
20170296760 | Lee et al. | Oct 2017 | A1 |
20180099088 | Gittard | Apr 2018 | A1 |
20180193574 | Smith | Jul 2018 | A1 |
20180214160 | Hoskins et al. | Aug 2018 | A1 |
20180339144 | Greenhalgh | Nov 2018 | A1 |
20190134366 | Erez et al. | May 2019 | A1 |
20190217315 | Maguire et al. | Jul 2019 | A1 |
20190232030 | Pic | Aug 2019 | A1 |
20210024187 | Fawcett et al. | Jan 2021 | A1 |
20210069485 | Rogier | Mar 2021 | A1 |
20210353912 | Kiev | Nov 2021 | A1 |
Number | Date | Country |
---|---|---|
101401956 | Nov 2012 | CN |
60215438 | Aug 2007 | DE |
0646385 | Apr 1995 | EP |
1033543 | Nov 2007 | EP |
3052168 | Nov 2019 | EP |
H07118305 | May 1995 | JP |
03013552 | Feb 2003 | WO |
2004066806 | Aug 2004 | WO |
2005062896 | Jul 2005 | WO |
2006071649 | Jul 2006 | WO |
2006088912 | Aug 2006 | WO |
2008033462 | Mar 2008 | WO |
2009061409 | May 2009 | WO |
2015050814 | Apr 2015 | WO |
2018157772 | Sep 2018 | WO |
Entry |
---|
Bridevaux, Pierre-Olivier, et al. “Short-term safety of thoracoscopic talc pleurodesis for recurrent primary spontaneous pneumothorax: a prospective European multicentre study.” European Respiratory Journal 38.4 (2011): 770-773. |
Giday, Samuel, et al. “Safety analysis of a hemostatic powder in a porcine model of acute severe gastric bleeding.” Digestive diseases and sciences 58.12 (2013): 3422-3428. |
Giday, Samuel A., et al. “A long-term randomized controlled trial of a novel nanopowder hemostatic agent for control of severe upper gastrointestinal bleeding in a porcine model.” Gastrointestinal Endoscopy 69.5 (2009): AB133. |
Giday, S. A., et al. “Long-term randomized controlled trial of a novel nanopowder hemostatic agent (TC-325) for control of severe arterial upper gastrointestinal bleeding in a porcine model.” Endoscopy 43.04 (2011): 296-299. |
Regalia, Kristen, et al. “Hemospray in Gastrointestinal Bleeding.” Practical Gastroenterology. Endoscopy: Opening New Eyes, ser. 8, May 2014, pp. 13-24. 8. |
Cook Medical. Hemospray Endoscopic Hemostat, Cook, 2014. (7 pages, in English). |
“Hemospray Clinical Experience Shows Efficacy of a New Hemostasis Modality—v1”, Cook Medical, 2012. |
“Hemospray Clinical Experience Shows Efficacy of a New Hemostasis Modality—v2”, Cook Medical, 2013. |
“Hemospray Clinical Experience Shows Efficacy of a New Hemostasis Modality—v3”, Cook Medical, 2014. |
Aslanian, Harry R., and Loren Laine. “Hemostatic powder spray for GI bleeding.” Gastrointestinal endoscopy 77.3 (2013): 508-510. |
Giday, S. A., et al. “Long-term randomized controlled trial of a novel nanopowder hemostatic agent (TC-325) for control of severe arterial upper gastrointestinal bleeding in a porcine model.” Endoscopy 43.04 (2011): 296-299. via ResearchGate. |
RETSCH GmbH Haan. Sieve Analysis: Taking a Close Look at Quality, An Expert Guide to Particle Size Analysis. 2015. (56 pages, in English). |
Micromeritics. Density Analysis, 2001. (6 pages, in English). |
Micromeritics. “Application Note: Bulk and Skeletal Density Computations for the AutoPore.” May 2012. (3 pages, in English). |
Arefnia, Ali, et al. “Comparative Study on the Effect of Tire-Derived Aggregate on Specific Gravity of Kaolin.” Electronic Journal of Geotechnical Engineering 18 (2013): 335-44. |
Kesavan, Jana, et al. “Density Measurements of Materials Used in Aerosol Studies”. Edgewood Chemical Biological Center Aberdeen Proving Ground MD, 2000. |
International Search Report and Written Opinion in related PCT/US2020/067175, dated Mar. 25, 2021 (English, 11 pages). |
Number | Date | Country | |
---|---|---|---|
20210205548 A1 | Jul 2021 | US |
Number | Date | Country | |
---|---|---|---|
62957540 | Jan 2020 | US |